Bridge Therapeutics is Selected as a Finalists for the RESI 2018 Innovation Challenge

Press Release ( - BIRMINGHAM, Ala. - Oct 31, 2018 - Bridge Therapeutics has been selected by Life Science Nation’s internal scientific review board to be part of the Innovation Challenge, presenting its technology in an exhibition-style format throughout the full-day RESI Conference on November 4, 2018, in New York. Being a Finalist gains Bridge additional exposure to investors and potential partners by showcasing its company and products through a dedicated poster in the Exhibit Hall.

Tim Peara, Bridge Therapeutics’ President says, “this poster shines a spotlight on Bridge and its plan to provide a safer treatment than opioids for chronic pain. It should catch investors’ eyes!”

RESI, or Redefining Early Stage Investments, is a conference series that is run by Life Science Nation that provides an international venue for early-stage life science companies to source investors, create relationships, and potentially secure funding.

To see the finalists for the Innovation Challenge Click Here

About Bridge Therapeutics

Bridge Therapeutics is an innovative, late development-stage specialty pharmaceutical company pursuing U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients. Its investigational drug BT-205 is a unique combination of two chronic pain drugs — the partial-agonist opioid buprenorphine and the NSAID meloxicam — delivered in a state-of-the-art sublingual formulation. Bridge Therapeutics’ goal is to make the BT-205 compound and other investigational new drug candidates available to millions of patients experiencing chronic pain.

Source : Bridge Therapeutics
Business Info :
Bridge Therapeutics Inc.

You may also like this  


Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login


If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.